Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment.
We evaluated the growth rate and pubertal status of 54 adolescent and young adult men with cystic fibrosis and assessed the efficacy of short-term androgen therapy in promoting growth and pubertal development. Thirty-nine percent were below the fifth percentile in height and 8/28 (28%) between the ages of 14 and 18 had delays in pubertal development. Five male adolescents aged 13 years 8 months to 18 years 3 months were treated with testosterone and their conditions were prospectively evaluated. Growth rate increased from an entry mean of 2.2 cm/yr (range 0 to 4 cm/yr) to 7.2 cm/yr (3 to 10 cm/yr). We conclude that a brief course of testosterone appears to be a safe, effective means of improving growth rate in male adolescents with cystic fibrosis with delay of puberty.
D000293:Adolescent; D000328:Adult; D000886:Anthropometry; D001827:Body Height; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications*; D005069:Evaluation Studies as Topic; D006128:Growth; D006130:Growth Disorders / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010555:Personality Inventory; D011446:Prospective Studies; D011628:Puberty, Delayed / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D012189:Retrospective Studies; D012737:Sex Factors; D013739:Testosterone / Q000627:therapeutic use*
D013739:Testosterone